Literature DB >> 15894262

De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent.

Karin E de Visser1, Lidiya V Korets, Lisa M Coussens.   

Abstract

Chronic inflammation predisposes tissue to cancer development; however, regulatory mechanisms underlying recruitment of innate leukocytes toward developing neoplasms are obscure. We report that genetic elimination of mature T and B lymphocytes in a transgenic mouse model of inflammation-associated de novo epithelial carcinogenesis, e.g., K14-HPV16 mice, limits neoplastic progression to development of epithelial hyperplasias that fail to recruit innate immune cells. Adoptive transfer of B lymphocytes or serum from HPV16 mice into T and B cell-deficient/HPV16 mice restores innate immune cell infiltration into premalignant tissue and reinstates necessary parameters for full malignancy, e.g., chronic inflammation, angiogenic vasculature, hyperproliferative epidermis. These findings support a model in which B lymphocytes are required for establishing chronic inflammatory states that promote de novo carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15894262     DOI: 10.1016/j.ccr.2005.04.014

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  297 in total

Review 1.  TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression.

Authors:  Li Yang; Yanli Pang; Harold L Moses
Journal:  Trends Immunol       Date:  2010-06-01       Impact factor: 16.687

Review 2.  Serologic laboratory findings in malignancy.

Authors:  Félix Fernández Madrid; Marie-Claire Maroun
Journal:  Rheum Dis Clin North Am       Date:  2011-11       Impact factor: 2.670

Review 3.  Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm.

Authors:  Subhra K Biswas; Alberto Mantovani
Journal:  Nat Immunol       Date:  2010-09-20       Impact factor: 25.606

4.  Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer.

Authors:  Andrew H Ko; Alexander C Jordan; Evan Tooker; Simon F Lacey; Renee B Chang; Yan Li; Alan P Venook; Margaret Tempero; Lloyd Damon; Lawrence Fong; Mark H O'Hara; Bruce L Levine; J Joseph Melenhorst; Gabriela Plesa; Carl H June; Gregory L Beatty
Journal:  Mol Ther       Date:  2020-07-21       Impact factor: 11.454

Review 5.  Nanoparticle design strategies for enhanced anticancer therapy by exploiting the tumour microenvironment.

Authors:  Yunlu Dai; Can Xu; Xiaolian Sun; Xiaoyuan Chen
Journal:  Chem Soc Rev       Date:  2017-05-18       Impact factor: 54.564

Review 6.  Neutralizing tumor-promoting chronic inflammation: a magic bullet?

Authors:  Lisa M Coussens; Laurence Zitvogel; A Karolina Palucka
Journal:  Science       Date:  2013-01-18       Impact factor: 47.728

7.  Lymphocyte-specific TRAF3 transgenic mice have enhanced humoral responses and develop plasmacytosis, autoimmunity, inflammation, and cancer.

Authors:  Juan M Zapata; David Llobet; Maryla Krajewska; Sophie Lefebvre; Christina L Kress; John C Reed
Journal:  Blood       Date:  2008-12-12       Impact factor: 22.113

8.  Inhibition of breast cancer metastasis by resveratrol-mediated inactivation of tumor-evoked regulatory B cells.

Authors:  Catalina Lee-Chang; Monica Bodogai; Alejandro Martin-Montalvo; Katarzyna Wejksza; Mitesh Sanghvi; Ruin Moaddel; Rafael de Cabo; Arya Biragyn
Journal:  J Immunol       Date:  2013-09-16       Impact factor: 5.422

Review 9.  Influence of tumour micro-environment heterogeneity on therapeutic response.

Authors:  Melissa R Junttila; Frederic J de Sauvage
Journal:  Nature       Date:  2013-09-19       Impact factor: 49.962

Review 10.  Innate and adaptive immune cells in the tumor microenvironment.

Authors:  Thomas F Gajewski; Hans Schreiber; Yang-Xin Fu
Journal:  Nat Immunol       Date:  2013-10       Impact factor: 25.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.